CNS

ProQR Launches Startup Focused on Central Nervous System Therapeutics

ProQR Therapeutics N.V., announced that the company has spun out Amylon Therapeutics (Amylon), a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders. Amylon will use the license and proceeds to continue research and development of therapies for CNS disorders, with an initial focus on a RNA-based treatment for a rare genetic disease that leads to strokes at mid-adulthood, called Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D). A future beta amyloid related indication could include cerebral amyloid angiopathy (CAA). ProQR retains majority ownership in Amylon and is entitled to future milestones and royalties from the products developed by Amylon on the terms and conditions set forth in the license.

Amylon will be led by Thomas de Vlaam as founding CEO, who holds a bachelor’s degree in international medicine and global health. Thomas joined ProQR in 2015 to incubate the CNS activities, with the goal of spinning it out into a new company. On behalf of ProQR, Dinko Valerio, the Chairman of the Supervisory board of ProQR, will…